Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 6.88
- Piotroski Score 6.00
- Grade Buy
- Symbol (TGTX)
- Company TG Therapeutics, Inc.
- Price $23.54
- Changes Percentage (0.04%)
- Change $0.01
- Day Low $23.10
- Day High $23.91
- Year High $25.70
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $23.00
- High Stock Price Target $49.00
- Low Stock Price Target $16.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.30
- Trailing P/E Ratio 52.83
- Forward P/E Ratio 52.83
- P/E Growth 52.83
- Net Income $12.67 M
Income Statement
Quarterly
Annual
Latest News of TGTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
TG Therapeutics Inc (NASDAQ:TGTX) A Bull Case Theory
TG Therapeutics (TGTX) is a biopharmaceutical company excelling in treatments for B-cell mediated diseases, with a promising flagship product, Briumvi, targeting Multiple Sclerosis. The company's fina...
By Yahoo! Finance | 1 week ago -
TG Therapeutics, Inc. (TGTX) Stock Price, News, Quote & History - Yahoo Finance
TG Therapeutics, Inc. is a biopharmaceutical company focusing on innovative treatments for B-cell mediated diseases. Their products include BRIUMVI for multiple sclerosis and Umbralisib for lymphoma. ...
By Yahoo! Finance | 1 month ago -
Insider Sale: Director Sagar Lonial Sells 25,933 Shares of TG Therapeutics Inc (TGTX)
TG Therapeutics Inc is a biopharmaceutical company specializing in treatments for B-cell malignancies and autoimmune diseases. Insider selling trends, stock valuation metrics, and GF Value estimates s...
By Yahoo! Finance | 2 months ago
